

# Kazufumi Ohshiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10132555/publications.pdf>

Version: 2024-02-01

9  
papers

269  
citations

1307594

7  
h-index

1474206

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

560  
citing authors

| # | ARTICLE  | IF   | CITATIONS |
|---|--|------|-----------|
| 1 | Impaired reciprocal regulation between SIRT6 and TGF- $\beta$ 2 signaling in fatty liver. <i>FASEB Journal</i> , 2022, 36, e22335.   | 0.5  | 6         |
| 2 | $\beta$ 2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. <i>Science Translational Medicine</i> , 2021, 13, eabk2267.                                    | 12.4 | 23        |
| 3 | Alterations in TGF- $\beta$ 2 signaling leads to high HMGA2 levels potentially through modulation of PJA1/SMAD3 in HCC cells. <i>Genes and Cancer</i> , 2020, 11, 43-52.   | 1.9  | 8         |
| 4 | A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- $\beta$ Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.   | 6.2  | 134       |
| 5 | PRAJA is overexpressed in glioblastoma and contributes to neural precursor development. <i>Genes and Cancer</i> , 2017, 8, 640-649.  | 1.9  | 11        |
| 6 | TGF- $\beta$ 2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. <i>Journal of Clinical Investigation</i> , 2016, 126, 527-542.                                     | 8.2  | 39        |
| 7 | MTA1 regulation of ER $\beta$ pathway in salivary gland carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 1016-1021.  | 2.1  | 5         |
| 8 | SUMOylation and SUMO-interacting Motif (SIM) of Metastasis Tumor Antigen 1 (MTA1) Synergistically Regulate Its Transcriptional Repressor Function*. <i>Journal of Biological Chemistry</i> , 2011, 286, 43793-43808. | 3.4  | 36        |
| 9 | Evolving pathway-driven biomarkers in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, S51-S56.   | 4.1  | 7         |